Invivyd (IVVD) AI Stock Analysis

• Market Cap: $71.98M
• Dividend Yield: N/A
• Average Volume (3M): 4.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: N/A
• EPS Growth: 20.91%
• Country: US
• Employees: 99
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -1.43
• Shares Outstanding: 119,961,450
• 10 Day Avg. Volume: 2,304,570
• 30 Day Avg. Volume: 4,567,724
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 7.63
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 1566.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Invivyd's overall stock score is primarily driven by its financial performance and valuation challenges. The company faces substantial operational losses and negative cash flows, despite recent revenue achievements. Technical analysis further indicates a bearish outlook, with the stock being oversold. Valuation concerns are underscored by a negative P/E ratio. While corporate events like the appointment of Ajay Royan to the board are positive, they have limited impact on the overall score.

Positive Factors

Clinical Data

Long-term data from the Phase 3 trial reported a 76% risk reduction in symptomatic COVID-19 over 12 months in immunocompetent individuals, suggesting broad protective durability.

Revenue Growth

Net revenue from PEMGARDA rose 48% sequentially in 4Q24, reflecting growing prescriber adoption and renewed confidence.

Negative Factors

Regulatory Challenges

The FDA has rejected Invivyd’s submission to expand PEMGARDA's Emergency Use Authorization to include COVID-19 treatment.

Sales Performance

IVVD reported 3Q24 Pemgarda net product revenue of $9.3mn, coming in well short of consensus at $32mn.

Invivyd Business Overview & Revenue Model

Company Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

How the Company Makes Money

Invivyd generates revenue primarily through the development and commercialization of its therapeutic products. The company invests in research and development to create proprietary monoclonal antibodies that can be licensed or sold to healthcare providers, pharmaceutical companies, or directly to the market. Revenue streams may include product sales, licensing agreements, and potential partnerships or collaborations with other pharmaceutical companies. These partnerships can involve co-development or co-marketing arrangements, which can significantly contribute to the company's earnings by leveraging shared resources and expertise.

Invivyd Financial Statement Overview

Summary

Invivyd faces significant financial challenges, marked by substantial losses and negative cash flows despite recent revenue generation. While the balance sheet shows low leverage and strong cash reserves, consistent operational losses and cash flow inefficiencies pose considerable risks. Strategic improvements in operational efficiency and revenue generation are critical for future stability.

Income Statement

Invivyd's financial performance shows a challenging trajectory. The company recorded its first revenue of $25.38 million in 2024 after having no revenue in previous years, indicating a significant growth. However, the company still faces substantial net losses, with a negative net profit margin due to high operational costs. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

Invivyd maintains a relatively strong equity position with a moderate debt load, as evidenced by a low debt-to-equity ratio. However, there has been a significant decrease in stockholders' equity over the years, and the equity ratio has declined, indicating potential risks if losses continue. The company's high cash reserves provide some financial stability.

Cash Flow

The company's cash flow situation is strained, with consistently negative free cash flow due to high operational cash outflows. The free cash flow to net income ratio remains unfavorable, indicating that the company is not generating cash from its operations. However, there is a positive trend in financing activities which have supported cash reserves.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
25.38M	0.00	0.00	0.00	0.00
	Gross Profit
23.77M	-2.03M	-462.00K	-1.00K	0.00
	EBIT
-176.88M	-207.78M	-248.03M	-226.91M	-65.33M
	EBITDA
-176.88M	-196.62M	-248.03M	-226.79M	-65.33M
	Net Income Common Stockholders
-169.93M	-198.64M	-234.60M	-234.29M	-65.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
69.35M	200.64M	371.99M	591.42M	114.99M
	Total Assets
129.51M	229.18M	383.17M	620.09M	117.38M
	Total Debt
1.30M	2.17M	3.72M	0.00	0.00
	Net Debt
-68.05M	-198.48M	-88.35M	-542.22M	-114.99M
	Total Liabilities
61.98M	51.71M	27.20M	62.07M	182.63M
	Stockholders Equity
67.54M	177.47M	355.97M	558.02M	-65.25M
Cash Flow		Free Cash Flow
-170.63M	-173.78M	-221.69M	-184.82M	-14.57M
	Operating Cash Flow
-170.49M	-173.16M	-219.99M	-184.74M	-14.57M
	Investing Cash Flow
-140.00K	280.68M	-230.67M	-50.71M	0.00
	Financing Cash Flow
39.33M	1.04M	506.00K	662.68M	129.56M

Invivyd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVVD, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.99, and below the 200-day MA of 0.94, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 32.90 is Neutral, neither overbought nor oversold. The STOCH value of 4.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVVD.

Invivyd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBX	58 Neutral	$202.52M	0.12	919.96%	―	―	―
BNTX	54 Neutral	$21.85B	―	-3.38%	―	-27.64%	-172.62%
VXRT	49 Neutral	$92.78M	―	-114.71%	―	288.94%	39.45%
Sector *	48 Neutral	$6.86B	1.11	-51.04%	2.47%	16.66%	1.53%
MRNA	48 Neutral	$12.01B	―	-28.77%	―	-52.75%	25.00%
IVVD	40 Underperform	$71.98M	―	-138.71%	―	―	20.91%
NVAX	39 Underperform	$1.03B	―	30.06%	―	-30.65%	77.62%

Invivyd Corporate Events

Invivyd Appoints Ajay Royan to Board of Directors

On March 22, 2025, Invivyd, Inc. appointed Ajay Royan, founder of Mithril Capital, to its Board of Directors, with his term expiring at the 2025 annual meeting of stockholders. Royan, a venture capitalist with a focus on healthcare, technology, and energy, will receive compensation consistent with other non-employee directors and was granted an option to acquire 100,000 shares of common stock. His appointment is expected to enhance Invivyd’s efforts to advance its monoclonal antibody technology platform, which aims to provide high-quality medicines for vulnerable populations affected by COVID-19 and other diseases.